Although our study demonstrates that charged ADCs can influence efficacy in HER2-positive xenograft models, we acknowledge that testing a broader range of tumor types, including HER2-low, HER2-negative, and patient-derived xenograft (PDX) models, is necessary for drawing more comprehensive conclusions. The gene discussed is ERBB2; the disease is neoplasm.